Angiogenesis as a therapeutic target
The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Abstract
Inhibiting angiogenesis is a promising strategy for treatment of cancer and several other disorders, including age-related macular degeneration. Major progress towards a treatment has been achieved over the past few years, and the first antiangiogenic agents have been recently approved for use in several countries. Therapeutic angiogenesis (promoting new vessel growth to treat ischaemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of vascular morphogenesis is needed first.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As compared to the traditional transwell method, the monolayer design also has the added advantage of easily generating shear stress.”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
In the citing paper
“This monolayer approach is very effective in applications where cylindrical vessel geometry of blood vessels is not very essential to the study, such as in the testing of drugs which prevent cancer cell migration because this method is high throughput and simple to fabricate [106].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
In the citing paper
“Shear stress helps cells arrange themselves to establish the barrier function [106].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“This followed from a phase III study showing a survival benefi”
BackgroundSelf-citationTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · cited 1×
“So far, VEGF-A and its receptors are the best-characterized signalling pathway in developmental angiogenesi”
BackgroundSelf-citationIsolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725 · cited 1×
“reported the isolation of putative EPC from human peripheral blood, on the basis of cell-surface expression of CD34 and other endothelial marker”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“An alternative hypothesis has been proposed by Jai”
BackgroundTrastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 1×
“Several fragments of larger proteins have been described as endogenous inhibitors of angiogenesis including endostati”
BackgroundOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“So far, VEGF-A and its receptors are the best-characterized signalling pathway in developmental angiogenesi”
BackgroundVascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Self-citation
Research works printed but not linked: 1
- Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209–5218 (1999).
Cited by
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Imaging in the era of molecular oncology
Weissleder, R., & Pittet, M. J. (2008) · Nature · doi:10.1038/nature06917 · Cited by 2,364
Shibuya, M. (2011) · Genes & Cancer · doi:10.1177/1947601911423031 · Cited by 1,748
“Molecular cloning, however, revealed that these 2 proteins were identical and encoded by a single gene.(3) The VEGF family includes VEGF-A, VEGFB, VEGF-C, VEGF-D, PlGF (placental growth factor), VEGF-E (Orf-VEGF), and Trimeresurus flavoviridis svVEGF.”
BackgroundInfluentialHypoxia signalling in cancer and approaches to enforce tumour regression
Pouysségur, J., Dayan, F., & Mazure, N. M. (2006) · Nature · doi:10.1038/nature04871 · Cited by 1,676
“The first good example of targeting an HIF-dependent gene product is the anti-VEGF-A therapeutic strateg”
BackgroundCombining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
“Vascular endothelial growth factor A (VEGFA) is best known for its effects on angiogenesi”
BackgroundIturria-Medina, Y., Sotero, R. C., Toussaint, P. J., Mateos-Pérez, J. M., Evans, A. C., Initiative, T. A. D. N., Weiner, M. W., Aisen, P., Petersen, R., Jack, C. R., et al. (2016) · Nature Communications · doi:10.1038/ncomms11934 · Cited by 1,202
“Among other functions, IP-10 is a strong modulator of angiogenesis 28 , which has a key role in poor vascularization and abnormal vasculature disorders 29 .”
Integrins in angiogenesis and lymphangiogenesis
Avraamides, C. J., Garmy-Susini, B., & Varner, J. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2353 · Cited by 1,050
“Basic and clinical studies indicate that suppression of angiogenesis can inhibit tumour progression and metastasi”
BackgroundAutocrine VEGF Signaling Is Required for Vascular Homeostasis
Lee, S., Chen, T. T., Barber, C. L., Jordan, M. C., Murdock, J., Desai, S., Ferrara, N., Nagy, A., Roos, K. P., & Iruela-Arispe, M. L. (2007) · Cell · doi:10.1016/j.cell.2007.06.054 · Cited by 1,046
Self-citationTen years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
“…, although subsequent studies revealed infrequent adverse events including gastrointestinal perforations, nephrotic syndrome and arterial thromboembolic complications such as myocardial infarction and stroke, especially in patients with a prior thromboembolic event or of age 65 or older 69,71,72 .”
BackgroundSelf-citationThe hypoxic tumour microenvironment
Petrova, V., Annicchiarico-Petruzzelli, M., Melino, G., & Amelio, I. (2018) · Oncogenesis · doi:10.1038/s41389-017-0011-9 · Cited by 1,019
Jang, S. C., Kim, O. Y., Yoon, C. M., Choi, D.-S., Roh, T.-Y., Park, J., Nilsson, J., Lötvall, J., Kim, Y.-K., & Gho, Y. S. (2013) · ACS Nano · doi:10.1021/nn402232g · Cited by 1,022
“Angiogenesis, the formation and growth of new blood vessels from the pre-existing vasculature, is critical for tumor growth.(37) 39 Although antiangiogenesis therapy does not guarantee complete tumor regression, it is considered a promising antitumor therapy.”
BackgroundChen, P.-L., Roh, W., Reuben, A., Cooper, Z. A., Spencer, C. N., Prieto, P. A., Miller, J. P., Bassett, R. L., Gopalakrishnan, V., Wani, K., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1545 · Cited by 988
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
Ridgway, J., Zhang, G., Wu, Y., Stawicki, S., Liang, W.-C., Chanthery, Y., Kowalski, J., Watts, R. J., Callahan, C., Kasman, I., et al. (2006) · Nature · doi:10.1038/nature05313 · Cited by 986
Claudon, M., Dietrich, C. F., Choi, B. I., Cosgrove, D. O., Kudo, M., Nolsøe, C. P., Piscaglia, F., Wilson, S. R., Barr, R. G., Chammas, M. C., et al. (2013) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2012.09.002 · Cited by 971
Cancer as an overhealing wound: an old hypothesis revisited
Schäfer, M., & Werner, S. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2455 · Cited by 956
“Likewise, numerous studies have highlighted the essential role of neovascularization in the growth of tumours beyond a diameter of 2 mm and in metastasi”
BackgroundKucharzewska, P., Christianson, H. C., Welch, J. E., Svensson, K. J., Fredlund, E., Ringnér, M., Mörgelin, M., Bourseau-Guilmain, E., Bengzon, J., & Belting, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220998110 · Cited by 939
Biological properties of “naked” metal nanoparticles☆
BHATTACHARYA, R., & MUKHERJEE, P. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.03.013 · Cited by 917
Targeting the EGFR signaling pathway in cancer therapy
Seshacharyulu, P., Ponnusamy, M. P., Haridas, D., Jain, M., Ganti, A. K., & Batra, S. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.648617 · Cited by 913
“EGFR signaling activation can stimulate the synthesis and secretion of a number of angiogenic regulating factors, such as vascular endothelial growth factor (VEGF), Interleukin-8 (IL-8) and basic fibroblast growth factor (bFGF) [134].”
BackgroundIntrinsic therapeutic applications of noble metal nanoparticles: past, present and future
Arvizo, R. R., Bhattacharyya, S., Kudgus, R. A., Giri, K., Bhattacharya, R., & Mukherjee, P. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15355f · Cited by 866
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849
Self-citationAntiangiogenic therapy in oncology: current status and future directions
Jayson, G. C., Kerbel, R., Ellis, L. M., & Harris, A. L. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01088-0 · Cited by 828
Self-citationBlocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation
Tammela, T., Zarkada, G., Wallgard, E., Murtomäki, A., Suchting, S., Wirzenius, M., Waltari, M., Hellström, M., Schomber, T., Peltonen, R., et al. (2008) · Nature · doi:10.1038/nature07083 · Cited by 813
Shibuya, M. (2013) · Journal of Biochemistry · doi:10.1093/jb/mvs136 · Cited by 792
Brahimi-Horn, M. C., Chiche, J., & Pouysségur, J. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0281-3 · Cited by 765
“HIF-mediated expression of gene products including the vascular endothelial growth factor-A (VEGF-A) and angiopoïetin-2 (Ang-2) allow tumour cells to turn around the hypoxic situation by inducing regrowth of the vascular network, a phenomenon termed angiogenesis [19].”
BackgroundDelta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting
Lobov, I. B., Renard, R. A., Papadopoulos, N., Gale, N. W., Thurston, G., Yancopoulos, G. D., & Wiegand, S. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611206104 · Cited by 774
Targeting the tumour vasculature: insights from physiological angiogenesis
Chung, A. S., Lee, J., & Ferrara, N. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2868 · Cited by 752
Self-citationAngiogenesis modulates adipogenesis and obesity
Cao, Y. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32239 · Cited by 736
Developmental and Pathological Angiogenesis
Chung, A. S., & Ferrara, N. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154002 · Cited by 722
Self-citationThe brain tumor microenvironment
Charles, N. A., Holland, E. C., Gilbertson, R., Glass, R., & Kettenmann, H. (2011) · Glia · doi:10.1002/glia.21136 · Cited by 718
The brain tumor microenvironment
Charles, N. A., Holland, E. C., Gilbertson, R., Glass, R., & Kettenmann, H. (2012) · Glia · doi:10.1002/glia.21264 · Cited by 712
Src kinases as therapeutic targets for cancer
Kim, L. C., Song, L., & Haura, E. B. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.129 · Cited by 700
“Angiogenesis is a multistep process that includes endothelial cell migration, invasion, and proliferation”
BackgroundDicer Dependent MicroRNAs Regulate Gene Expression and Functions in Human Endothelial Cells
Suárez, Y., Fernández-Hernando, C., Pober, J. S., & Sessa, W. C. (2007) · Circulation Research · doi:10.1161/01.res.0000265065.26744.17 · Cited by 698
Adenosine, an endogenous distress signal, modulates tissue damage and repair
Fredholm, B. B. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402132 · Cited by 686
“Indeed, blockade of angiogenesis provides additional benefit in tumor therapy.(42) The formation of functional blood vessels appears to require”
BackgroundAnti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan, R. R., Griffioen, A. W., & Duda, D. G. (2017) · Angiogenesis · doi:10.1007/s10456-017-9552-y · Cited by 672
Bv8 regulates myeloid-cell-dependent tumour angiogenesis
Shojaei, F., Wu, X., Zhong, C., Yu, L., Liang, X.-H., Yao, J., Blanchard, D., Bais, C., Peale, F. V., van Bruggen, N., et al. (2007) · Nature · doi:10.1038/nature06348 · Cited by 644
Self-citationCrawford, Y., Kasman, I., Yu, L., Zhong, C., Wu, X., Modrusan, Z., Kaminker, J., & Ferrara, N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.004 · Cited by 611
“Targeting VEGF-A, in combination with chemotherapy, is efficacious in treating several human tumors (Ellis and Hicklin, 2008; Ferrara and Kerbel, 2005; Kerbel, 2008).”
BackgroundSelf-citationSiemann, D. W. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.05.001 · Cited by 611
Zimna, A., & Kurpisz, M. (2015) · BioMed Research International · doi:10.1155/2015/549412 · Cited by 604
“The activation of the most prominent proangiogenic factor VEGF might be due to physiological stimuli such as hypoxia or inflammation or due to oncogene activation and tumour suppression function loss [18, 19].”
BackgroundTumour vascularization: sprouting angiogenesis and beyond
Hillen, F., & Griffioen, A. W. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9094-7 · Cited by 583
Heger, M., van Golen, R. F., Broekgaarden, M., & Michel, M. C. (2014) · Pharmacological Reviews · doi:10.1124/pr.110.004044 · Cited by 576
Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective
Kowanetz, M., & Ferrara, N. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1520 · Cited by 564
Self-citationClaudon, M., Dietrich, C., Choi, B., Cosgrove, D., Kudo, M., Nolsøe, C., Piscaglia, F., Wilson, S., Barr, R., Chammas, M., et al. (2012) · Ultraschall in der Medizin - European Journal of Ultrasound · doi:10.1055/s-0032-1325499 · Cited by 550
Emerging role of adipose tissue hypoxia in obesity and insulin resistance
Ye, J. (2009) · International Journal of Obesity · doi:10.1038/ijo.2008.229 · Cited by 543
Blocking Neuropilin-1 Function Has an Additive Effect with Anti-VEGF to Inhibit Tumor Growth
Pan, Q., Chanthery, Y., Liang, W.-C., Stawicki, S., Mak, J., Rathore, N., Tong, R. K., Kowalski, J., Yee, S. F., Pacheco, G., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.10.018 · Cited by 532
Coronary arteries form by developmental reprogramming of venous cells
Red-Horse, K., Ueno, H., Weissman, I. L., & Krasnow, M. A. (2010) · Nature · doi:10.1038/nature08873 · Cited by 541
The tumor microenvironment and its contribution to tumor evolution toward metastasis
Lorusso, G., & Rüegg, C. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0530-8 · Cited by 531
“inhibition or even regression of angiogenic vessels (Ferrara and Kerbel 2005).”
BackgroundLampugnani, M. G., Orsenigo, F., Gagliani, M. C., Tacchetti, C., & Dejana, E. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200602080 · Cited by 525
“VEGF is a major growth factor for endothelial cells and plays an important role in the formation of new vessels during embryogenesis and in proliferative diseases (Alitalo et al., 2005; Carmeliet, 2005; Ferrara and Kerbel, 2005).”
BackgroundCell migration into scaffolds under co-culture conditions in a microfluidic platform
Chung, S., Sudo, R., Mack, P. J., Wan, C.-R., Vickerman, V., & Kamm, R. D. (2009) · Lab Chip · doi:10.1039/b807585a · Cited by 519
Biology and therapeutic targeting of vascular endothelial growth factor A
Pérez-Gutiérrez, L., & Ferrara, N. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00631-w · Cited by 484
“The reasons for such disappointing results have been extensively debated but, among various possibilities, it is conceivable that young and healthy animals inadequately modelled the extensive atherosclerotic disease observed in patients 229 .”
BackgroundSelf-citationDietrich, C. F., Nolsøe, C. P., Barr, R. G., Berzigotti, A., Burns, P. N., Cantisani, V., Chammas, M. C., Chaubal, N., Choi, B. I., Clevert, D.-A., et al. (2020) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2020.04.030 · Cited by 498
“Neoangiogenesis is an important target for novel anticancer treatments and many new antiangiogenesis or antivascular treatments aim at destroying or limiting the growth of tumor vessels [241, 242].”
BackgroundVenneri, M. A., Palma, M. D., Ponzoni, M., Pucci, F., Scielzo, C., Zonari, E., Mazzieri, R., Doglioni, C., & Naldini, L. (2007) · Blood · doi:10.1182/blood-2006-10-053504 · Cited by 505
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
Verheul, H. M. W., & Pinedo, H. M. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2152 · Cited by 503
“Specific inhibitors of angiogenesis have been identified and developed to block tumour growth and metastasis formation using preclinical in vitro and in vivo model”
MethodUse of the mouse aortic ring assay to study angiogenesis
Baker, M., Robinson, S. D., Lechertier, T., Barber, P. R., Tavora, B., D'Amico, G., Jones, D. T., Vojnovic, B., & Hodivala-Dilke, K. (2012) · Nature Protocols · doi:10.1038/nprot.2011.435 · Cited by 477
“Angiogenic processes involve the stimulation of endothelial cells by several different pro-angiogenic factors such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and other”
BackgroundShojaei, F., Wu, X., Qu, X., Kowanetz, M., Yu, L., Tan, M., Meng, Y. G., & Ferrara, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902280106 · Cited by 471
“A is important in several pathophysiological processes (1, 2).”
BackgroundSelf-citationAntiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer?
Kerbel, R. S. (2006) · Science · doi:10.1126/science.1125950 · Cited by 466
Self-citationMolecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role
Wang, X., Bove, A. M., Simone, G., & Ma, B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.599281 · Cited by 442
“…of blood vessels from precursor cells during early embryogenesis and the formation of blood vessels from preexisting vessels at a later stage, and increase vascular permeability and chemotaxis of vascular endothelial cells (Ferrara and Kerbel, 2005; Benedito et al., 2012; Chen et al., 2013).”
BackgroundChang, Y. S., Adnane, J., Trail, P. A., Levy, J., Henderson, A., Xue, D., Bortolon, E., Ichetovkin, M., Chen, C., McNabola, A., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0393-4 · Cited by 459
“Y. S. Chang (&) · J. Adnane · P. A. Trail · A. Henderson · D. Xue · E. Bortolon · M. Ichetovkin Department of Protein Therapeutics, Bayer Research Center, Bayer HealthCare, Pharmaceuticals, 400 Morgan Lane, West Haven, CT 06516, USA e-mail: yong.chang.b@bayer.com J. Levy · C. Chen · A. McNabola · D. Wilkie · C. A. Car…”
BackgroundInfluentialAn interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
Chung, A. S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.-M., Jiang, Z., Meng, Y. G., Peale, F. V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3291 · Cited by 445
Self-citationGeiger, T. R., & Peeper, D. S. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.07.006 · Cited by 431
Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases
Cao, Y. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3055 · Cited by 442
“Angiogenic factors such as VEGFA have broad biological functions even under physiological conditions, including de novo formation of the vascular system during embryonic development, neurotrophic and neuroprotective activity, tissue and organ regeneration, maintenance of vascular integrity and maintenance of vascular…”
BackgroundTumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma
Ahir, B. K., Engelhard, H. H., & Lakka, S. S. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01892-8 · Cited by 424
Lee, C., Kim, M.-J., Kumar, A., Lee, H.-W., Yang, Y., & Kim, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02249-0 · Cited by 365
Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment
Mader, J. S., & Hoskin, D. W. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.8.933 · Cited by 430
“A promising development has been in the area of therapeutic agents that restrict or abrogate the blood supply to solid tumours [7]; however, emerging evidence that tumours can develop resistance to the current generation of angiogenesis inhibitors [8] underscores the need for additional novel approaches to cancer trea…”
BackgroundP53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis
Yamakuchi, M., Lotterman, C. D., Bao, C., Hruban, R. H., Karim, B., Mendell, J. T., Huso, D., & Lowenstein, C. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911082107 · Cited by 430
“M solid tumors require angiogenesis to grow beyond a certain size (1, 2).”
BackgroundNotch signaling in vascular development and physiology
Gridley, T. (2007) · Development · doi:10.1242/dev.004184 · Cited by 429
“…of xenograft tumor models in rodents, in clinical trials, anti-VEGFA antibody treatment of several cancer types has been found to only provide an overall survival benefit for patients when it is combined with conventional chemotherapy treatment (Ferrara and Kerbel, 2005; Jain et al., 2006).”
BackgroundGenes that Distinguish Physiological and Pathological Angiogenesis
Seaman, S., Stevens, J., Yang, M. Y., Logsdon, D., Graff-Cherry, C., & St. Croix, B. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.04.017 · Cited by 419
“Angiogenesis is required for the progression of many diseases, including age-related macular degeneration and cancer (Kerbel and Folkman, 2002; Ferrara and Kerbel, 2005).”
BackgroundPericyte–fibroblast transition promotes tumor growth and metastasis
Hosaka, K., Yang, Y., Seki, T., Fischer, C., Dubey, O., Fredlund, E., Hartman, J., Religa, P., Morikawa, H., Ishii, Y., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608384113 · Cited by 415
“Curr Opin Investig Drugs 2(3):422–423.”
BackgroundSennino, B., Ishiguro-Oonuma, T., Wei, Y., Naylor, R. M., Williamson, C. W., Bhagwandin, V., Tabruyn, S. P., You, W.-K., Chapman, H. A., Christensen, J. G., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0240 · Cited by 408
“Treatment with the anti-VEGF monoclonal antibody bevacizumab, usually administered with chemotherapy, delays progression and prolongs the survival of some patients (1, 2).”
BackgroundAxon Guidance Molecules in Vascular Patterning
Adams, R. H., & Eichmann, A. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001875 · Cited by 405
A repertoire of biomedical applications of noble metal nanoparticles
Azharuddin, M., Zhu, G. H., Das, D., Ozgur, E., Uzun, L., Turner, A. P. F., & Patra, H. K. (2019) · Chemical Communications · doi:10.1039/c9cc01741k · Cited by 395
Karamysheva, A. F. (2008) · Biochemistry (Moscow) · doi:10.1134/s0006297908070031 · Cited by 386
M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis
Kubota, Y., Takubo, K., Shimizu, T., Ohno, H., Kishi, K., Shibuya, M., Saya, H., & Suda, T. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081605 · Cited by 388
“M-CSF inhibition selectively suppresses tumor angiogenesis and lymphangiogenesis The mechanisms underlying developmental angiogenesis and lymphangiogenesis may impact tumor angiogenesis and lymphangiogenesis (1, 2, 32); thus, we hypothesized that MCSF–targeted therapies selectively suppress tumor angio genesis and l…”
Background3D microtumors in vitro supported by perfused vascular networks
Sobrino, A., Phan, D. T. T., Datta, R., Wang, X., Hachey, S. J., Romero-López, M., Gratton, E., Lee, A. P., George, S. C., & Hughes, C. C. W. (2016) · Scientific Reports · doi:10.1038/srep31589 · Cited by 387
Oxygen, a source of life and stress
Brahimi-Horn, M. C., & Pouysségur, J. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.06.018 · Cited by 383
The transcriptional coactivator PGC-1α mediates exercise-induced angiogenesis in skeletal muscle
Chinsomboon, J., Ruas, J., Gupta, R. K., Thom, R., Shoag, J., Rowe, G. C., Sawada, N., Raghuram, S., & Arany, Z. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909131106 · Cited by 379
Cancer prevention and therapy through the modulation of the tumor microenvironment
Casey, S. C., Amedei, A., Aquilano, K., Azmi, A. S., Benencia, F., Bhakta, D., Bilsland, A. E., Boosani, C. S., Chen, S., Ciriolo, M. R., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.02.007 · Cited by 372
Peptides Containing β-Amino Acid Patterns: Challenges and Successes in Medicinal Chemistry
Cabrele, C., Martinek, T. A., Reiser, O., & Berlicki, Ł. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5010896 · Cited by 368
Ovarian cancer cell-secreted exosomal miR-205 promotes metastasis by inducing angiogenesis
He, L., Zhu, W., Chen, Q., Yuan, Y., Wang, Y., Wang, J., & Wu, X. (2019) · Theranostics · doi:10.7150/thno.37455 · Cited by 367
Becker, J., Semler, O., Gilissen, C., Li, Y., Bolz, H. J., Giunta, C., Bergmann, C., Rohrbach, M., Koerber, F., Zimmermann, K., et al. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.01.015 · Cited by 362
The role of the EGFR signaling in tumor microenvironment
De Luca, A., Carotenuto, A., Rachiglio, A., Gallo, M., Maiello, M. R., Aldinucci, D., Pinto, A., & Normanno, N. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21260 · Cited by 359
“Actually, angiogenesis is mediated by positive and negative regulators whose balance determines the rate of vessel formation (Ferrara and Kerbel, 2005).”
BackgroundMacrophages: An Inflammatory Link Between Angiogenesis and Lymphangiogenesis
Corliss, B. A., Azimi, M. S., Munson, J. M., Peirce, S. M., & Murfee, W. L. (2016) · Microcirculation · doi:10.1111/micc.12259 · Cited by 356
“There are numerous outstanding reviews chronicling the structure [78], function [125], mechanistic regulation [294], and inhibition [80,126] of tumor-associated blood vessels.”
BackgroundAlbuquerque, R. J. C., Hayashi, T., Cho, W. G., Kleinman, M. E., Dridi, S., Takeda, A., Baffi, J. Z., Yamada, K., Kaneko, H., Green, M. G., et al. (2009) · Nature Medicine · doi:10.1038/nm.2018 · Cited by 357
“Pathological responses of these parallel circulatory systems can lead to diseases as varied as age-related macular degeneration, atherosclerosis, cancer, lymphedema, rheumatoid arthritis and tumor metastasi”
BackgroundLichtenberger, B. M., Tan, P. K., Niederleithner, H., Ferrara, N., Petzelbauer, P., & Sibilia, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.046 · Cited by 358
“It is accepted that VEGF produced by tumor cells acts on neighboring VEGFR-expressing ECs to promote neovascularization for continued tumor growth (Bergers and Benjamin, 2003; Ferrara et al., 2003; Ferrara and Kerbel, 2005).”
InfluentialSelf-citationBronckaers, A., Hilkens, P., Martens, W., Gervois, P., Ratajczak, J., Struys, T., & Lambrichts, I. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.02.013 · Cited by 354
An overview of small-molecule inhibitors of VEGFR signaling
Ivy, S. P., Wick, J. Y., & Kaufman, B. M. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.130 · Cited by 350
“In neoplasms, tumor-derived factors promote angiogenesis, which includes multiple processes such as cell division, migration, normal growth patterns and progression until vessels can function”
BackgroundVEGF-A Links Angiogenesis and Inflammation in Inflammatory Bowel Disease Pathogenesis
Scaldaferri, F., Vetrano, S., Sans, M., Arena, V., Straface, G., Stigliano, E., Repici, A., Sturm, A., Malesci, A., Panes, J., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.09.064 · Cited by 340
Ferrari, G., Cook, B. D., Terushkin, V., Pintucci, G., & Mignatti, P. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21706 · Cited by 340
Van der Veldt, A. A. M., Lubberink, M., Bahce, I., Walraven, M., de Boer, M. P., Greuter, H. N. J. M., Hendrikse, N. H., Eriksson, J., Windhorst, A. D., Postmus, P. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.023 · Cited by 337
“Consequently, numerous drugs have been developed to target the signaling pathways of VEGF and its receptors (VEGFR; Ferrara and Kerbel, 2005).”
BackgroundMouse models of breast cancer metastasis
Fantozzi, A., & Christofori, G. (2006) · Breast Cancer Research · doi:10.1186/bcr1530 · Cited by 331
“Induction of angiogenesis precedes the formation of malignant tumors, and increased vascularization seems to correlate with the invasive properties of tumors and thus with the malignant tumor phenotype [13].”
BackgroundType-2 pericytes participate in normal and tumoral angiogenesis
Birbrair, A., Zhang, T., Wang, Z.-M., Messi, M. L., Olson, J. D., Mintz, A., & Delbono, O. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00084.2014 · Cited by 333
“The goal of therapeutic angiogenesis is to treat ischemia by stimulating new blood vessel growth from existing vessels (35, 36, 44).”
BackgroundRole of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression
Shojaei, F., Singh, M., Thompson, J. D., & Ferrara, N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712185105 · Cited by 334
“I t is now well established that angiogenesis plays a crucial role in tumor progression (1).”
BackgroundSelf-citationVEGF-A: a critical regulator of blood vessel growth
Ferrara, N. (2009) · European Cytokine Network · doi:10.1684/ecn.2009.0170 · Cited by 327
“Angiogenesis is a complex process that results in the establishment of microvascular networks required for pre/postnatal development and for tissue repair in the adult [1-4].”
BackgroundSelf-citationPark, J.-S., Kim, I.-K., Han, S., Park, I., Kim, C., Bae, J., Oh, S. J., Lee, S., Kim, J. H., Woo, D.-C., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.018 · Cited by 327
“Traditional anti-angiogenic approaches have focused mainly on the suppression of new vessel formation and destruction of pre-existing tumor vessels to starve tumor cells (Cao et al., 2011; Ferrara and Kerbel, 2005; Kim et al., 2014).”
BackgroundZhao, T., Li, J., & Chen, A. F. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00192.2010 · Cited by 329
“Accordingly, precise control of angiogenesis has been identified as a potential therapeutic strategy by, for instance, either promoting angiogenesis of ischemic tissues or inhibiting angiogenesis in tumor cells (11).”
BackgroundGoodson, W. H., Lowe, L., Carpenter, D. O., Gilbertson, M., Manaf Ali, A., Lopez de Cerain Salsamendi, A., Lasfar, A., Carnero, A., Azqueta, A., Amedei, A., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv039 · Cited by 322
“Tumor growth, invasion and metastasis depend on blood vessels and neovascular development to provide nutrients, oxygen and removal of metabolic waste as tumors grow in primary sites, invade adjacent tissues and metastasize to distant organs (387,388).”
BackgroundSupramolecular nanostructures that mimic VEGF as a strategy for ischemic tissue repair
Webber, M. J., Tongers, J., Newcomb, C. J., Marquardt, K.-T., Bauersachs, J., Losordo, D. W., & Stupp, S. I. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016546108 · Cited by 324
“In addition, a number of synthetic strategies have emerged to modulate angiogenesis through small molecules or peptides and have been developed to antagonize receptors for cancer therapies or to promote angiogenesis by signaling through these receptors (28, 29).”
Targeting the tumor stroma for cancer therapy
Xu, M., Zhang, T., Xia, R., Wei, Y., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01670-1 · Cited by 319
HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
Shojaei, F., Lee, J. H., Simmons, B. H., Wong, A., Esparza, C. O., Plumlee, P. A., Feng, J., Stewart, A. E., Hu-Lowe, D. D., & Christensen, J. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0489 · Cited by 319
“Members of vascular endothelial growth factor (VEGF) signaling pathway play a key role in both physiologic and pathologic angiogenesis; hence, recent Food and Drug Administration (FDA) approval of bevacizumab (an anti-VEGF monoclonal antibody) opened a new era in cancer therapy (1).”
BackgroundSILVA, E. A., & MOONEY, D. J. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02386.x · Cited by 316
Pathways mediating VEGF-independent tumor angiogenesis
Ferrara, N. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.003 · Cited by 313
“FGF gene families (reviewed in [4–6]) and various inhibitors of angiogenesis such as thrombospondin, endostatin and tumstatin”
BackgroundSelf-citation
Metadata
- Authors
- Ferrara, N., & Kerbel, R. S.
- Affiliations
- Genentech (US)
- Sunnybrook Health Science Centre (CA)
- Corresponding author
- Ferrara, Napoleone
- Venue
- Nature
- Published
- 2005-12
- Volume
- 438
- Issue
- 7070
- Pages
- 967-974
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2084740377
- Semantic Scholar
- 19591ab68a155b2d341266c48a9ef957bd4ba612
- Cited by
- 2,653
- References
- 102
- Citations by year
- 2026: 39 · 2025: 57 · 2024: 72 · 2023: 69 · 2022: 75 · 2021: 102 · 2020: 114 · 2019: 95 · 2018: 97 · 2017: 124 · 2016: 160 · 2015: 164 · 2014: 158 · 2013: 171 · 2012: 164
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- Canadian Institutes of Health Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- angiogenesis, anti-angiogenic therapy, therapeutic angiogenesis, cancer therapy, age-related macular degeneration, antiangiogenic drugs, vascular morphogenesis
- MeSH terms
- Animals, Bone Marrow Cells, Clinical Trials as Topic, Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Drug Resistance, Neoplasm, Angiogenesis Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.